INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ON Semiconductor Corporation

Onsemi faces an investor lawsuit investigation by Pomerantz LLP over potential securities fraud or unlawful business practices. Separately, Onsemi’s planned all-stock acquisition of Synaptics was valued at about $7B (1.35 shares of ON for each SYNA share), but Onsemi shares dropped $28.09 (-23.66%) to $90.65 on June 26, 2026 following the deal announcement.

Analysis

The market is signaling that the issue is not legal optics but capital allocation credibility. In semis, an all-stock deal is only as good as the buyer’s equity currency; once the stock gaps lower, every future acquisition and employee-retention package becomes more expensive, and that usually compresses the acquirer’s multiple versus peers for several quarters. ON is the obvious loser, but the deeper knock-on is to other serial consolidators in analog/embedded if investors decide this is a warning against using inflated strategic narratives to justify dilution.

SYNA is not insulated just because it is the target. Its takeout value is effectively a leveraged claim on ON’s shares, so any continued weakness in ON creates a mechanical discount in SYNA and raises deal-break risk if financing optics worsen. Competitors with steadier organic execution — TXN, ADI, MCHP, STM — can gain relative appeal as customers and sell-side investors migrate toward names with less integration distraction and cleaner free-cash-flow conversion.

Near term, the catalyst path is less about the lawsuit itself and more about whether management can defend the transaction with hard accretion math, not synergy slogans, into the next earnings cycle. The thesis breaks if ON re-establishes its pre-deal valuation on improved guidance or if the exchange ratio is adjusted in a way that restores perceived fairness. Longer term, if the deal closes, the market will want proof that cross-sell and cost savings offset product overlap; otherwise the acquisition becomes a multi-quarter margin drag rather than a growth catalyst.

The consensus may be overfocusing on litigation as a binary headline when the real risk is a permanent repricing of ON’s M&A currency. That is why the reaction matters more than the complaint: the stock is acting like investors fear management has traded optionality for scale at the wrong point in the cycle. If so, the best expression is relative short exposure, not a standalone lawsuit trade.

Key Decisions for Investors

• Short ON vs. long SOXX for the next 1-3 months: express underperformance from deal-dilution and litigation overhang, with a target of 10-15% relative downside if management cannot quickly prove accretion; cover if ON guidance and post-deal economics are reaffirmed on the next earnings call.
• Pair long TXN / short ON on a 1-3 month horizon: TXN offers cleaner capital allocation and less integration risk, while ON faces lower equity currency and higher execution uncertainty; best risk/reward if the spread widens on any relief rally in ON.
• Avoid chasing SYNA outright until the exchange ratio discount stabilizes: the name is effectively tethered to ON’s stock price, so any further weakness in ON can mechanically bleed through even if the transaction remains intact.
• Set an alert on ON’s next earnings and proxy materials: if free cash flow guidance or margin commentary weakens, treat that as a thesis-confirming signal to add to the short; if ON reclaims the pre-announcement valuation and management demonstrates clear accretion, the negative case is likely fading.